EVFM — Evofem Biosciences Share Price
0.000.00%
Last trade - 00:00- $1.02m
- $51.55m
- $19.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.03 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -34.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.45 | 8.24 | 16.84 | 18.22 | 19.36 | 193.32 | 241.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +100 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. Its first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Using its platform, women can have a telehealth visit with a health care provider to determine their eligibility for a Phexxi prescription. It is also focused on commercializing SOLOSEC (secnidazole) 2g oral granules that address two pervasive sexual health infections.
Directors
- Saundra Pelletier PRE (51)
- Justin File CFO (50)
- Alexander Fitzpatrick EVP (54)
- Russell Barrans OTH (61)
- Kelly Culwell OTH (47)
- Gillian Greer IND (76)
- Kim Kamdar IND (53)
- Tony O'Brien IND (58)
- Lisa Rarick IND (61)
- Colin Rutherford IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 1st, 2007
- Public Since
- November 20th, 2014
- No. of Shareholders
- 14
- No. of Employees
- 32
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 113,356,354
- Address
- 12400 High Bluff Drive, Suite 600, SAN DIEGO, 92130
- Web
- https://www.evofem.com/
- Phone
- +1 8585501900
- Contact
- Amy Raskopf
- Auditors
- BPM LLP
Upcoming Events for EVFM
Q2 2025 Evofem Biosciences Inc Earnings Release
Similar to EVFM
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Evofem Biosciences share price?
As of Today at 20:34 UTC, shares in Evofem Biosciences are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Evofem Biosciences share price performed this year?
Shares in Evofem Biosciences last closed at $0.01 and the price had moved by -30.77% over the past 365 days. In terms of relative price strength the Evofem Biosciences share price has underperformed the S&P500 Index by -35.8% over the past year.
What are the analyst and broker recommendations for Evofem Biosciences?
The overall consensus recommendation for Evofem Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Evofem Biosciences dividend yield?
Evofem Biosciences does not currently pay a dividend.
Does Evofem Biosciences pay a dividend?
Evofem Biosciences does not currently pay a dividend.
When does Evofem Biosciences next pay dividends?
Evofem Biosciences does not currently pay a dividend.
How do I buy Evofem Biosciences shares?
To buy shares in Evofem Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evofem Biosciences?
As of the previous close price of $0.01, shares in Evofem Biosciences had a market capitalisation of $1.02m.
Where are Evofem Biosciences shares listed?
Here are the trading details for Evofem Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EVFM
What kind of share is Evofem Biosciences?
Based on an overall assessment of its quality, value and momentum Evofem Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evofem Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Evofem Biosciences is $225.00. That is 2499900% above the last closing price of $0.01.
Analysts covering Evofem Biosciences currently have a consensus Earnings Per Share (EPS) forecast of $0.23 for the next financial year.
Find out moreWhat is the trend in the Evofem Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evofem Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -36%.
As of the last closing price of $0.01, shares in Evofem Biosciences were trading -6.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evofem Biosciences PE Ratio?
The Evofem Biosciences PE ratio based on its reported earnings over the past 12 months is 0.03. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evofem Biosciences?
Evofem Biosciences' management team is headed by:
- Saundra Pelletier - PRE
- Justin File - CFO
- Alexander Fitzpatrick - EVP
- Russell Barrans - OTH
- Kelly Culwell - OTH
- Gillian Greer - IND
- Kim Kamdar - IND
- Tony O'Brien - IND
- Lisa Rarick - IND
- Colin Rutherford - IND